First Citizens BancShares Free cash flow decreased by 96.2% to $31.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 720.0%, from -$5.00M to $31.00M. Over 3 years (FY 2022 to FY 2025), Free cash flow shows a downward trend with a -5.7% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase suggests improved operational efficiency or reduced capital intensity, providing more flexibility for capital allocation. A decrease may indicate higher investment in R&D or infrastructure, or potential challenges in converting earnings into cash.
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and m...
Large-cap medical device and pharmaceutical peers typically maintain strong, positive free cash flow, though levels vary based on the intensity of R&D spending and the lifecycle stage of major product lines.
free_cash_flow| Q2 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | -$717.00M | $562.00M | $630.00M | $464.00M | $980.00M | -$406.00M | $832.00M | $1.14B | $693.00M | $367.00M | $316.00M | $885.00M | $991.00M | -$5.00M | $733.00M | $678.00M | $807.00M | $31.00M |
| QoQ Change | — | +178.4% | +12.1% | -26.3% | +111.2% | -141.4% | +304.9% | +36.5% | -39.0% | -47.0% | -13.9% | +180.1% | +12.0% | -100.5% | >999% | -7.5% | +19.0% | -96.2% |
| YoY Change | — | — | +187.9% | — | — | -172.2% | +32.1% | +144.8% | -29.3% | +190.4% | -62.0% | -22.1% | +43.0% | -101.4% | +132.0% | -23.4% | -18.6% | +720.0% |